{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:19:36Z","timestamp":1791580776767,"version":"4.3.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lecanemab and Aducanumab are two novel anti-amyloid beta (A\u03b2) therapies for Alzheimer\u2019s disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited real-world evidence. This study aims to analyze and compare adverse drug reactions (ADRs) of these drugs using data from the WHO-VigiAccess and FAERS databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted using ADR data from the VigiAccess and FAERS databases, focusing on System Organ Class (SOC) and Preferred Term (PT) classifications. Descriptive statistics and reporting odds ratio (ROR) analysis were employed to evaluate and compare ADR profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Lecanemab and Aducanumab exhibited distinct ADRs. Results from both the VigiAccess and FAERS databases indicated that the most SOC associated with both drugs was nervous system disorders (34.7% in VigiAccess, 36.8% in FAERS). Further multivariable logistic regression analysis revealed that Aducanumab was associated with a higher risk of nervous system disorders (OR = 4.72, 95% CI: 3.53\u20136.39, P &amp;lt; 0.001). Among the reported AEs, headache was the most frequently reported for Lecanemab (9.4% in VigiAccess, 8.96% in FAERS), while Aducanumab was primarily associated with amyloid-related imaging abnormalities (ARIA) (19.1% in VigiAccess, 23.58% in FAERS). In the blood and lymphatic systems, Anemia was observed in both drugs. However, thrombocyto-penia was more prevalent in Lecanemab, while platelet dysfunction and myelosuppression were more frequently observed in Aducanumab. Additionally, hospitalization and mortality rates were higher for Aducanumab compared to Lecanemab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study compared the ADRs of Lecanemab and Aducanumab, revealing that ARIA was the most common AE for both drugs. However, Lecanemab showed a lower risk of ARIA, cerebral hemorrhage, and severe events. These findings emphasize the need for further clinical research to clarify the long-term safety and efficacy of both drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1561020","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T09:46:53Z","timestamp":1744364813000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases"],"prefix":"10.3389","volume":"16","author":[{"given":"Haoxiang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiesheng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1007\/s10072-024-07477-w","article-title":"The efficacy and safety of lecanemab 10 mg\/kg biweekly compared to a placebo in patients with alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Abdelazim","year":"2024","journal-title":"Neurol. Sci."},{"key":"B2","unstructured":"Aducanumab discontinued as alzheimer\u2019s treatment | alz.org\n          \n          \n          2024"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"102620","DOI":"10.1016\/j.arr.2024.102620","article-title":"Monoclonal therapy with lecanemab in the treatment of mild alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"104","author":"Arroyo-Pacheco","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3233\/JAD-230040","article-title":"Playing Russian roulette with alzheimer\u2019s disease patients: do the cognitive benefits of lecanemab outweigh the risk of edema, stroke and encephalitis?","volume":"92","author":"Atwood","year":"2023","journal-title":"JAD"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100043","DOI":"10.1016\/j.tjpad.2024.100043","article-title":"17th clinical trials on alzheimer\u2019s disease (CTAD) madrid Spain, october 29 - november 1, 2024: Symposia, oral communications","volume":"12","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1288362","DOI":"10.3389\/fphar.2024.1288362","article-title":"Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)","volume":"15","author":"Bao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and management of amyloid-related imaging abnormalities in patients with alzheimer\u2019s disease treated with anti-amyloid beta therapy","volume":"9","author":"Barakos","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on alzheimer\u2019s disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"B10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s12975-013-0288-8","article-title":"Thrombin-induced cerebral hemorrhage: role of protease-activated receptor-1","volume":"5","author":"Cheng","year":"2014","journal-title":"Transl. Stroke Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/cpt.2954","article-title":"Physician perspectives on the food and drug administration's decision to grant accelerated approval to aducanumab for Alzheimer's disease","volume":"114","author":"Dhruva","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1412006","DOI":"10.3389\/fnagi.2024.1412006","article-title":"Three major effects of APOE\u03b54 on a\u03b2 immunotherapy induced ARIA","volume":"16","author":"Foley","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40120-021-00273-0","article-title":"Predicted lifetime health outcomes for aducanumab in patients with early alzheimer\u2019s disease","volume":"10","author":"Herring","year":"2021","journal-title":"Neurol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early alzheimer\u2019s disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","article-title":"Ageing as a risk factor for neurodegenerative disease","volume":"15","author":"Hou","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1503154","DOI":"10.3389\/fphar.2024.1503154","article-title":"Characterizing ADRs of enfortumab vedotin and erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40265-024-02087-4","article-title":"Donanemab: first approval","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Euro J Neurology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"102199","DOI":"10.1016\/j.arr.2024.102199","article-title":"Recent trends in treatment strategies for alzheimer\u2019s disease and the challenges: a topical advancement","volume":"94","author":"Liu","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e207919","DOI":"10.1212\/WNL.0000000000207919","article-title":"Genome-wide association studies of ARIA from the aducanumab phase 3 ENGAGE and EMERGE studies","volume":"102","author":"Loomis","year":"2024","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"q1692","DOI":"10.1136\/bmj.q1692","article-title":"Lecanemab: European drug agency rejects alzheimer\u2019s drug amid debate over efficacy and safety","volume":"386","author":"Mahase","year":"2024","journal-title":"BMJ"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.37765\/ajmc.2020.88481","article-title":"Current and evolving treatment strategies for the alzheimer disease continuum","volume":"26","author":"Marasco","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/s41591-022-02062-0","article-title":"The long road to a cure for alzheimer\u2019s disease is paved with failures","volume":"28","author":"Moutinho","year":"2022","journal-title":"Nat. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e209582","DOI":"10.1212\/WNL.0000000000209582","article-title":"Refractory status epilepticus in a patient with aducanumab-induced amyloid-related imaging abnormalities","volume":"103","author":"Neves Briard","year":"2024","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","article-title":"Review of statistical methodologies for detecting drug-drug interactions using spontaneous reporting systems","volume":"10","author":"Noguchi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/psyg.12944","article-title":"Aducanumab for the treatment of alzheimer\u2019s disease: a systematic review","volume":"23","author":"Rahman","year":"2023","journal-title":"Psychogeriatrics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/d41586-023-00030-3","article-title":"FDA approves alzheimer\u2019s drug lecanemab amid safety concerns","volume":"613","author":"Reardon","year":"2023","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces a\u03b2 plaques in alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"10868","DOI":"10.1038\/s41598-024-61691-2","article-title":"Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities","volume":"14","author":"S\u00f6derberg","year":"2024","journal-title":"Sci. Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for alzheimer\u2019s disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early alzheimer\u2019s disease with lecanemab, an anti-a\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/14737175.2024.2402058","article-title":"Profiling aducanumab as a treatment option for alzheimer\u2019s disease: an overview of efficacy, safety and tolerability","volume":"24","author":"Thussu","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40264-018-0706-7","article-title":"A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries","volume":"41","author":"Tieu","year":"2018","journal-title":"Drug Saf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.14283\/jpad.2024.106","article-title":"Japanese subgroup analyses from EMERGE and ENGAGE, phase 3 clinical trials of aducanumab in patients with early alzheimer\u2019s disease","volume":"11","author":"Toda","year":"2024","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","article-title":"The path forward in alzheimer\u2019s disease therapeutics: reevaluating the amyloid cascade hypothesis","volume":"16","author":"Tolar","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B44","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.3390\/ijms22126355","article-title":"Neurotoxic soluble amyloid oligomers drive alzheimer\u2019s pathogenesis and represent a clinically validated target for slowing disease progression","volume":"22","author":"Tolar","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/CIA.S325026","article-title":"Role of aducanumab in the treatment of alzheimer\u2019s disease: challenges and opportunities","volume":"17","author":"Vaz","year":"2022","journal-title":"Clin. Interv. Aging"},{"key":"B47","doi-asserted-by":"publisher","first-page":"n1682","DOI":"10.1136\/bmj.n1682","article-title":"Aducanumab for alzheimer\u2019s disease?","volume":"374","author":"Walsh","year":"2021","journal-title":"BMJ"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1439115","DOI":"10.3389\/fphar.2024.1439115","article-title":"Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1561020\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T09:46:55Z","timestamp":1744364815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1561020\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":48,"alternative-id":["10.3389\/fphar.2025.1561020"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1561020","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"1561020"}}